Refractory Multiple Myeloma Emerging Drugs, Clinical Trials, and Pipeline Report 2024

DelveInsight's, "Refractory Multiple Myeloma Pipeline Insight, 2024," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Refractory Multiple Myeloma Treatment Drugs @ Refractory Multiple Myeloma Infection Pipeline Report- https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
• DelveInsight's Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Refractory Multiple Myeloma treatment.
• The leading companies working in the Refractory Multiple Myeloma Market include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
• Promising Refractory Multiple Myeloma Pipeline Therapies in the various stages of development include Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.
• March 2024: Caribou Biosciences Inc. announced a study of Phase 1 clinical trials for CB-011. This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
• December 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Linvoseltamab, Elotuzumab, Pomalidomide and Dexamethasone. This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of the study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone (called "EPd" in this form), one of these standard treatment options. Half of the participants in this study will get linvoseltamab, and the other half will get EPd. Both linvoseltamab and EPd will be referred to as "study drugs" in this form.

In the Refractory Multiple Myeloma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Find out more about Refractory Multiple Myeloma Treatment Drugs @ Drugs for Refractory Multiple Myeloma Treatment- https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Refractory Multiple Myeloma Overview
Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It's relatively rare, making up less than 2 percent, but it's the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn't effective at completely getting rid of the cancer in the vast majority.

Refractory Multiple Myeloma Emerging Drugs Profile

Felzartamab: MorphoSys
Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.

RAPA-201: Rapa Therapeutics
RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.

PHE885: Novartis
PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.

ABBV 453: AbbVie
ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.

Refractory Multiple Myeloma Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase II include, MorphoSys.

Learn more about the emerging Refractory Multiple Myeloma Pipeline Therapies @ Refractory Multiple Myeloma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

DelveInsight's Refractory Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Refractory Multiple Myeloma Pipeline Report
• Coverage- Global
• Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Refractory Multiple Myeloma Companies- NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
• Refractory Multiple Myeloma Pipeline Therapies- Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.

Dive deep into rich insights for new drugs for Refractory Multiple Myeloma treatment, Visit @ Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Refractory Multiple Myeloma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Refractory Multiple Myeloma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. NEXI 002: NexImmune
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ABBV 453: AbbVie
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Refractory Multiple Myeloma Key Companies
21. Refractory Multiple Myeloma Key Products
22. Refractory Multiple Myeloma- Unmet Needs
23. Refractory Multiple Myeloma- Market Drivers and Barriers
24. Refractory Multiple Myeloma- Future Perspectives and Conclusion
25. Refractory Multiple Myeloma Analyst Views
26. Refractory Multiple Myeloma Key Companies
27. Appendix

For further information on the Refractory Multiple Myeloma pipeline therapeutics, reach out @ Refractory Multiple Myeloma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.